Revolutionizing Gene Therapy: RGX-121 Presentation Highlights
REGENXBIO Inc. (NASDAQ: RGNX) is making waves in the field of gene therapy, particularly with its promising product RGX-121. This therapeutic approach targets mucopolysaccharidosis type II (MPS II), a rare and serious condition often referred to as Hunter syndrome. At a significant event on the horizon, the company will unveil critical data regarding RGX-121 at a major symposium.
Upcoming Presentations at the WORLD Symposium
REGENXBIO has announced that pivotal data from its RGX-121 program will be presented at the 21st Annual WORLD Symposium. This event is set to be a platform for researchers, clinicians, and industry leaders to exchange groundbreaking knowledge regarding advancements in rare disease therapies. The presentations scheduled for this symposium illustrate the ongoing commitment to advancing treatment options in rare genetic disorders.
Key Presentation Details
Highlighted among the presentations is an encore of the topline results from the pivotal phase of the Phase I/II/III CAMPSIITE trial. This research examines the efficacy and safety of RGX-121 in participants suffering from MPS II, contributing to a larger understanding of this challenging condition. The details of the presentations are as follows:
- Abstract Title: Audiology assessment of participants in CAMPSIITE, a phase I/II/III study of RGX-121 in neuronopathic MPS II (Poster 35). Presenter: Nidal Boulos, Ph.D., Director, Clinical Science, REGENXBIO. Date/Time: February 5, 2025; 3:30 p.m. PT.
- Abstract Title: CAMPSIITE Phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic MPS II. Presenter: Paul Harmatz, M.D., UCSF Benioff Children's Hospital. Date/Time: February 6, 2025; 8:30 a.m. PT.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has emerged as a pioneering force in the biotech industry, specifically focusing on the transformative potential of gene therapies. The company is dedicated to improving lives by leveraging AAV (adeno-associated virus) therapeutics, an innovative class of gene therapy medicines.
REGENXBIO's robust pipeline includes treatments for a variety of rare and retinal diseases, with RGX-202 aimed at addressing Duchenne muscular dystrophy and ABBV-RGX-314 developed in collaboration with AbbVie for conditions like wet age-related macular degeneration (AMD) and diabetic retinopathy. The company’s commitment to innovation is evident in its ambitious goal of facilitating one-time treatments that could radically shift healthcare delivery globally.
Exploration of Gene Therapy's Future
The vision behind REGENXBIO continually seeks to redefine patient care through groundbreaking treatment options. Thousands of patients have benefited from the AAV therapeutic platform, showcasing the potential for such treatments in addressing complex genetic disorders. The impressive strides made by REGENXBIO underline the importance of ongoing research and development in the biotechnology sphere.
Frequently Asked Questions
What is RGX-121 used for?
RGX-121 is an investigational gene therapy for treating mucopolysaccharidosis type II (Hunter syndrome).
When will the RGX-121 data be presented?
The data will be presented at the 21st Annual WORLD Symposium from February 3-7, 2025.
Who is presenting the RGX-121 data?
Nidal Boulos, Ph.D., and Paul Harmatz, M.D., will present key findings related to RGX-121.
What does REGENXBIO focus on?
REGENXBIO focuses on the development of gene therapies, particularly AAV therapeutics for rare and retinal diseases.
How long has REGENXBIO been operating?
REGENXBIO has been in operation since 2009, continuously striving to innovate in gene therapy.
